Claire Mauduit

Claire Mauduit

Auto-generated profile, based on publicly available information

Claire Mauduit

Hospices Civils de Lyon, Department of Pathology, Claude Bernard Lyon 1 University, Lyon Sud Hospital, Pierre-Bénite, Lyon, France

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in Biology of Reproduction
Verified
Journal Article
Open access
PDF file
AOAsma Omezzine
Asma Omezzine
CMClaire Mauduit
Claire Mauduit
ETEric Tabone
Eric Tabone
NNNaoufel Nabli
Naoufel Nabli
ABAli Bouslama
Ali Bouslama
MBMohamed Benahmed
Mohamed Benahmed
Although the apoptotic cell death process in the prostate is known to be under the control of androgens, the key components targeted by the hormones r

1 July 2020 in Human Pathology
Verified
Journal Article
Closed access
LGLucie Gaillot-Durand
Lucie Gaillot-Durand
SPSophie Patrier
Sophie Patrier
JAJacqueline Aziza
Jacqueline Aziza
LDLouise Devisme
Louise Devisme
ARAnne-Claude Riera
Anne-Claude Riera
FAFabienne Allias
Fabienne Allias

22 March 2025 in European Journal of Cancer
Verified
Journal Article
Open access
LRLoïc Renaud
Loïc Renaud
MDMarie Donzel
Marie Donzel
JDJustine Decroocq
Justine Decroocq
PDPierre Decazes
Pierre Decazes
JGJean Galtier
Jean Galtier
Vincent CamusVincent Camus
Vincent Camus
Primary mediastinal B-cell lymphoma (PMBCL) is a distinct subtype of large B-cell lymphoma with unique clinical, histopathological, and molecular characteristics. Despite its aggressive nature, PMBCL has a high cure rate when managed appropriately. Advances in the understanding of PMBCL biological characteristics, coupled with improvements in diagnostic tools and therapeutic approaches, have significantly improved patient outcomes in recent years. In this article, we present a set of pragmatic guidelines developed by the Lymphoma Study Association (LYSA) for the management of PMBCL. These guidelines address key aspects of diagnosis, staging, response evaluation, and treatment, integrating the latest evidence from clinical trials, expert consensus, and real-world practice. The aim of the guidelines is to provide clinicians with a clear, practical framework to optimize care for patients with PMBCL, ensuring that the best available evidence is translated into clinical practice.

6 April 2021 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
FSFabrizio Serra
Fabrizio Serra
SBSilvia BOTTINI
Silvia BOTTINI
DPDavid Pratella
David Pratella
MSMaria G. Stathopoulou
Maria G. Stathopoulou
WSWanda Sebille
Wanda Sebille
MTMichele Trabucchi
Michele Trabucchi
MicroRNAs (miRNAs) associate with Ago proteins to post-transcriptionally silence gene expression by targeting mRNAs. To characterize the modes of miRNA-binding, we developed a novel computational framework, called optiCLIP, which considers the reproducibility of the identified peaks among replicates based on the peak overlap. We identified 98 999 binding sites for mouse and human miRNAs, from eleven Ago2 CLIP-seq datasets. Clustering the binding preferences, we found heterogeneity of the mode of binding for different miRNAs. Finally, we set up a quantitative model, named miRgame, based on an adaptation of the game theory. We have developed a new algorithm to translate the miRgame into a score that corresponds to a miRNA degree of occupancy for each Ago2 peak. The degree of occupancy summarizes the number of miRNA-binding sites and miRNAs targeting each binding site, and binding energy of each miRNA::RNA heteroduplex in each peak. Ago peaks were stratified accordingly to the degree of occupancy. Target repression correlates with higher score of degree of occupancy and number of miRNA-binding sites within each Ago peak. We validated the biological performance of our new method on miR-155-5p. In conclusion, our data demonstrate that miRNA-binding sites within each Ago2 CLIP-seq peak synergistically interplay to enhance target repression.